Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionet TherapeuticsROCO:7808 12 Quick Ratio is 19.18 as of Dec. 2025, which is 9% below its 10-year median of 21.19. GuruFocus rates ROCO:7808 with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Bionet Therapeutics ranks better than 91.57% on this metric.
Bionet Therapeutics has a quick ratio of 19.18. It generally indicates good short-term financial strength.
The historical rank and industry rank for Bionet Therapeutics's Quick Ratio or its related term are showing as below:
ROCO:7808'
s Quick Ratio Range Over the Past 10 Years
Min: 9.98 Med: 21.19 Max: 43.68
Current: 19.18
During the past 4 years, Bionet Therapeutics's highest Quick Ratio was 43.68. The lowest was 9.98. And the median was 21.19.
ROCO:7808's Quick Ratio is ranked better than 91.57% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs ROCO:7808: 19.18
Bionet Therapeutics (ROCO:7808) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Bionet Therapeutics Quick Ratio Related Terms
Bionet Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Bionet Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7808 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Bionet Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionet Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bionet Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Bionet Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Bionet Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionet Therapeutics (ROCO:7808) has a Quick Ratio of 19.18 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Bionet Therapeutics and its competitors. This is near median its historical median of 21.19. Over the past decade, Bionet Therapeutics' Quick Ratio has ranged from 9.98 to 43.68. According to the industry distribution chart, Bionet Therapeutics ranks #119 out of 1411 companies in the Biotechnology industry, placing it in the top 8.4%.
Is Bionet Therapeutics' Quick Ratio too high?
Bionet Therapeutics' current Quick Ratio of 19.18 is near median its 10-year median of 21.19. Over the past 10 years, this metric has ranged from a low of 9.98 to a high of 43.68. The Biotechnology industry median Quick Ratio is 3.59. Bionet Therapeutics' value of 19.18 is 434.3% above this industry median. Based on the distribution chart, Bionet Therapeutics ranks #119 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bionet Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bionet Therapeutics' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bionet Therapeutics ranks #119 out of 1411 companies for Quick Ratio. This places Bionet Therapeutics in the top 8% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.59. Bionet Therapeutics' value of 19.18 is 434.3% above this benchmark. Historically, Bionet Therapeutics' own Quick Ratio has ranged from 9.98 to 43.68 over the past decade. While the company's 10-year median is 21.19 vs. the industry median of 3.59, Bionet Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionet Therapeutics's current Quick Ratio of 19.18 is 434.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Bionet Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionet Therapeutics's current Quick Ratio is 19.18, which is near median its own 10-year median of 21.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet Therapeutics stock overvalued right now?
Bionet Therapeutics (ROCO:7808) has a current Quick Ratio of 19.18. The current Quick Ratio is 19.18, which is near median its 10-year median of 21.19 and 434.3% above the Biotechnology industry median of 3.59. Bionet Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Bionet Therapeutics (ROCO:7808), the current Quick Ratio is 19.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
12GF Score
Get the complete analysis for ROCO:7808
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7808 has been successfully added to your 
